Open Access
Issue
Published:
23 February 2022
Atypical miller-fisher syndrome after COVID-19 and sleeve gastrectomy: Contribution of neurochemical markers to early diagnosis
),
Download citation
461
Views
31
Downloads
2
Crossref
N/A
WoS
0
Scopus
N/A
CSCD
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began in late 2019. More recently, there have been sporadic case reports on development of Miller-Fisher Syndrome, a rare variant of Guillain-Barré Syndrome in COVID-19 patients.
We reported herein the case of a French young women presenting with ophtalmoplegia, cerebellar ataxia, and universal areflexia following a bariatric surgery (sleeve gastrectomy). A concomitant COVID-19 diagnosis was retained based on microbiological testing. The patient was successfully treated after high-dose intravenous thiamine, but areflexia persisted. Underlying COVID-19 related Miller-Fisher Syndrome was established on physical examination and confirmed by pathologic neurophysiological findings and elevated level of phosphorylated neurofilament heavy chain protein in cerebrospinal fluid analysis.
Guillain-Barré Syndrome and its variants after SARS-CoV-2 infection are extremely rare. The measurement of phosphorylated neurofilament heavy chain protein should be considered as an easy tool to detect an early affection of the peripheral nervous system.
menu
Atypical miller-fisher syndrome after COVID-19 and sleeve gastrectomy: Contribution of neurochemical markers to early diagnosis
),
Abstract
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began in late 2019. More recently, there have been sporadic case reports on development of Miller-Fisher Syndrome, a rare variant of Guillain-Barré Syndrome in COVID-19 patients.
We reported herein the case of a French young women presenting with ophtalmoplegia, cerebellar ataxia, and universal areflexia following a bariatric surgery (sleeve gastrectomy). A concomitant COVID-19 diagnosis was retained based on microbiological testing. The patient was successfully treated after high-dose intravenous thiamine, but areflexia persisted. Underlying COVID-19 related Miller-Fisher Syndrome was established on physical examination and confirmed by pathologic neurophysiological findings and elevated level of phosphorylated neurofilament heavy chain protein in cerebrospinal fluid analysis.
Guillain-Barré Syndrome and its variants after SARS-CoV-2 infection are extremely rare. The measurement of phosphorylated neurofilament heavy chain protein should be considered as an easy tool to detect an early affection of the peripheral nervous system.
References(15)
M.A. Ellul, L. Benjamin, B. Singh, et al., Neurological associations of COVID-19, Lancet Neurol. sept 19 (9) (2020) 767‑83.
H. Zhao, D. Shen, H. Zhou, et al., Guillain-Barré syndrome associated with SARS–CoV-2 infection: causality or coincidence? Lancet Neurol. mai 19 (5) (2020) 383‑4.
J.A. Reyes-Bueno, L. García-Trujillo, P. Urbaneja, et al., Miller-Fisher syndrome after SARS-CoV-2 infection, Eur J Neurol. sept 27 (9) (2020) 1759‑61.
B. Al Othman, J. Raabe, A. Kini, et al., Update: the Miller Fisher variants of Guillain-Barré syndrome, Curr Opin Ophthalmol 30 (6) (2019) 462‑6 nov.
Z. Arányi, T. Kovács, I. Sipos, et al., Miller Fisher syndrome: brief overview and update with a focus on electrophysiological findings, Eur J Neurol. janv 19 (1) (2012) 15‑20 e1-3.
M. De Luca, A. Sartori, A. Vitiello, et al., Complications and mortality in a cohort of patients undergoing emergency and elective surgery with perioperative SARS-CoV-2 infection: an Italian multicenter study. Teachings of Phase 1 to be brought in Phase 2 pandemic, Updat Surg. avr 73 (2) (2021) 745‑52.
M. Gulinac, I.P. Novakov, S. Antovic, et al., Surgical complications in COVID-19 patients in the setting of moderate to severe disease, World J Gastrointest Surg. 27 août 13 (8) (2021) 788‑95.
B.M. Koffman, L.J. Greenfield, I.I. Ali, et al., Neurologic complications after surgery for obesity, Muscle Nerve. févr 33 (2) (2006) 166‑76.
R. Saab, M. El Khoury, S Farhat, Wernicke's encephalopathy three weeks after sleeve gastrectomy, Surg Obes Relat Dis Off J Am Soc Bariatr Surg 10 (5) (2014) 992‑4 oct.
R. Galvin, G. Bråthen, A. Ivashynka, et al., EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy, Eur J Neurol. déc 17 (12) (2010) 1408‑18.
M. Senel, S. Abu-Rumeileh, D. Michel, et al., Miller-Fisher syndrome after COVID-19: neurochemical markers as an early sign of nervous system involvement, Eur J Neurol 27 (11) (2020) 2378‑80 nov.
C. Dufour, T. -K. Co, A. Liu, GM1 ganglioside antibody and COVID-19 related Guillain Barre Syndrome - A case report, systemic review and implication for vaccine development, Brain Behav Immun - Health. mars 12 (2021) 100203.
J.B. Caress, R.J. Castoro, Z. Simmons, et al., COVID-19-associated Guillain-Barré syndrome: the early pandemic experience, Muscle Nerve 62 (4) (2020) 485‑91 oct.
B.R. Wakerley, A. Uncini, N. Yuki, GBS Classification Group, GBS Classification Group. Guillain-Barré and Miller Fisher syndromes–new diagnostic classification, Nat Rev Neurol. sept 10 (9) (2014) 537‑44.
I. Dujmovic, M.P. Lunn, M.M. Reilly, et al., Serial cerebrospinal fluid neurofilament heavy chain levels in severe Guillain-Barré syndrome, Muscle Nerve. juill 48 (1) (2013) 132‑4.
Publication history
Copyright
Rights and permissions
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
FEEDBACK 
TOP